Shannon Elizabeth Marshall

US Patent:

8338569, Dec 25, 2012

Filed:

Aug 4, 2009

Appl. No.:

12/535479

Inventors:

Shannon Marshall - Baltimore MD, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US

Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA

International Classification:

C07K 14/50
C07K 14/705
C07H 21/04

US Classification:

530351, 530350, 4241841, 514 76, 536 231, 536 234

Abstract:

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

US Patent:

20120276095, Nov 1, 2012

Filed:

Aug 31, 2010

Appl. No.:

13/392811

Inventors:

Solomon Langermann - Baltimore MD, US
Linda Liu - Clarksville MD, US
Joseph R. Podojil - Downers Grove IL, US
Stephen D. Miller - Oak Park IL, US
Shannon Marshall - Baltimore MD, US

International Classification:

A61K 39/395
A61P 29/00
C07K 19/00

US Classification:

4241341, 5303873

Abstract:

Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

US Patent:

20130004492, Jan 3, 2013

Filed:

Sep 12, 2012

Appl. No.:

13/612044

Inventors:

Shannon Marshall - Baltimore MD, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US

Assignee:

FIVE PRIME THERAPEUTIC INC. - South San Francisco CA

International Classification:

A61K 39/395
A61P 35/00
A61K 38/02
C07K 2/00
C07K 19/00

US Classification:

4241341, 530300, 5303873, 530362, 514 91

Abstract:

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

US Patent:

20140044738, Feb 13, 2014

Filed:

Apr 19, 2012

Appl. No.:

14/111402

Inventors:

Solomon Langermann - Baltimore MD, US
Linda Liu - Clarksville MD, US
Shannon Marshall - Baltimore MD, US
Sheng Yao - Columbia MD, US

Assignee:

AMPLIMMUNE, INC. - Gaithersburg MD

International Classification:

C07K 16/28
G01N 33/68
A61K 39/395

US Classification:

4241721, 5303898, 5303873, 5303913, 435188, 5303917, 435 721, 435 5

Abstract:

The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.

US Patent:

20160130348, May 12, 2016

Filed:

Oct 29, 2015

Appl. No.:

14/926732

Inventors:

- Gaithersburg MD, US
Linda Liu - Clarksville MD, US
Shannon Marshall - Baltimore MD, US
Sheng Yao - Columbia MD, US

International Classification:

C07K 16/28

Abstract:

The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.

US Patent:

20160039905, Feb 11, 2016

Filed:

Apr 6, 2015

Appl. No.:

14/679497

Inventors:

- Gaithersburg MD, US
Linda Liu - Clarksville MD, US
Joseph R. Podojil - Downers Grove IL, US
Stephen D. Miller - Oak Park IL, US
Shannon Marshall - Baltimore MD, US

International Classification:

C07K 14/705

Abstract:

Fusion proteins containing B7-II4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by Th1, Th1 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

US Patent:

20140356364, Dec 4, 2014

Filed:

Aug 15, 2012

Appl. No.:

14/239117

Inventors:

Solomon Langermann - Baltimore MD, US
Linda Liu - Clarksville MD, US
Shannon Marshall - Baltimore MD, US

Assignee:

AMPLIMMUNE, INC. - Gaithersburg MD

International Classification:

C07K 16/28
C07K 16/30

US Classification:

4241361, 5303897, 506 14, 5303913, 5303917, 435188, 53038885, 5303873, 4241721, 4241331, 4241561, 4241741, 4241521

Abstract:

The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.